InvestLog
LENZ LENZ Therapeutics, Inc. logo

LENZ LENZ Therapeutics, Inc.

Healthcare
$7.55+0.40%ClosedMarket Cap: $236.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.96

P/S

11.28

EV/EBITDA

-1.80

DCF Value

$2.43

FCF Yield

-36.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

91.2%

Operating Margin

-563.8%

Net Margin

-519.3%

ROE

-46.8%

ROA

-40.0%

ROIC

-48.0%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$1.9M$-41.5M$—
Q4 null$1.6M$-35.9M$—
FY null$19.1M$-82.1M$—
Q3 null$12.5M$-16.7M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$12.00

Target (Median)

$12.00

Target Range

$12.00 - $12.00

1 Strong Buy6 Buy1 Hold0 Sell0 Strong Sell
CitigroupBuy
2026-05-13
HC Wainwright & Co.Buy
2026-05-12
Piper SandlerNeutral
2026-05-12
CitigroupBuy
2026-03-26
B of A SecuritiesBuy
2026-03-25

Trading Activity

Insider Trades

View All
Schimmelpennink Evert B.director, officer: President, CEO and Secretary
BuyMon Mar 30
George Jeffrey P.director
BuyMon Mar 30
Chevallard Daniel R.officer: Chief Financial Officer
BuyMon Mar 30
Schimmelpennink Evert B.director, officer: President, CEO and Secretary
SellTue Jan 06
Olsson Shawnofficer: Chief Commercial Officer
SellTue Jan 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

1.67

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Peers

ABUS logoABUSGERN logoGERNGHRS logoGHRSMRVI logoMRVINBTX logoNBTXPRME logoPRMERZLT logoRZLTSPRY logoSPRYSVRA logoSVRATYRA logoTYRA